Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In India Reversal, 44 Fixed-Dose Combination Drugs To Get June Approval

This article was originally published in PharmAsia News

Executive Summary

India's Drug Controller General of India has reversed itself and given approval to 44 of 294 combination drugs it originally rejected as irrational. The fixed-dose combinations include treatments for diarrhea, fever, hypertension and pain. The 44 cleared by the DGCI are expected to be approved in June, subject to the Drug Technical Advisory Board, which is expected to give its final approval soon. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts